On October 18, 2022 Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us"), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, reported that it has approved 4 additional clinical trial sites for IMX-110 clinical trials, complementing existing soft tissue sarcoma lead clinical trial site in California (Press release, Immix Biopharma, OCT 18, 2022, View Source [SID1234622129]). Historically, the lead high-enrolling site has enrolled 2-3 patients per month. Once dosing begins, patients will undergo CT scans every 8 weeks to assess tumor response to IMX-110; results are expected to be released on a rolling basis beginning in Q1 2023.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited to select these 4 preeminent oncology sites to join our clinical site consortium from a larger group of interested centers. We are humbled by the enthusiasm from these key opinion leaders to bring IMX-110 to their patients," said Ilya Rachman, MD PhD, CEO of ImmixBio. "These KOLs are excited about both IMX-110 as a monotherapy, and in combination with BeiGene and Novartis’ anti-PD-1, tislelizumab."
About IMX-110
The U.S. Food and Drug Administration ("FDA") has approved orphan drug designation ("ODD") for IMX-110 for the treatment of soft tissue sarcoma. Additionally, the FDA has approved rare pediatric disease designation ("RPDD") for IMX-110 for the treatment of a life-threatening pediatric cancer in children, rhabdomyosarcoma. RPDD qualifies ImmixBio to receive fast track review and a priority review voucher (PRV) at the time of marketing approval of IMX-110. IMX-110 is currently being evaluated in a phase 1b/2a clinical trial in patients with advanced solid tumors. Learn more at www.immixbio.com/iMX-110